Welcome to the Ihub Arrayit Corporation (ARYC) board
Arrayit Corporation (ARYC) is a Silicon Valley biotech company that is currently trading at a low fraction of its actual worth. Please review the listed links, see the actual sales of this Silicon Valley company through their daily updates on Twitter (@Arrayit) and understand the incredible potential that this company has.
927 Thompson Place
Sunnyvale, CA 94085
Publications and Social Networking:
Arrayit products have been featured in 5,000+ scientific publications. https://twitter.com/arrayit
Follow Arrayit on Twitter, Facebook, Yahoo Finance, $ARYC and iHub.
https://finance.yahoo.com/quote/ARYC?ltr=1 https://www.youtube.com/ Arrayit Corporation News Feed
Arrayit Corporation is a leading life sciences company providing innovative products and services to empower scientists and clinicians to explore the human genome as well as the genomes of plants and animals. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. Novel insights into the function of genes and proteins, early stage disease diagnostics, better and safer medicines, and more nutritional crop plants are some of the many aspects of human health empowered by Arrayit technology.
Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Our corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as our highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for our customers in the research, pharmaceutical, diagnostic, and health care markets.
Arrayit Corporation was founded in 1993 by Rene' Schena and Todd Martinsky as TeleChem International, Inc, a chemical import and export company specializing in plastics, water soluble fertilizers, alternative fuels, and the life sciences. After several years of successful revenues growth, the company expanded in 1999 by adding Dr. Mark Schena and Paul Haje, who together with Ms. Schena and Mr. Martinsky, founded Arrayit Life Sciences, a division of TeleChem International, Inc. Arrayit sought to build on the opportunities created by the deciphering of the human genome and the rise of microarray technology. Arrayit microarrays are sophisticated glass substrates containing large collections of DNA and protein spots that allow all 25,000 human genes and every major protein in the human body to be analyzed in a few hours. Arrayit VIP™ microarrays enable the analysis of the DNA from 100,000 patients in one day. Since 1999, Arrayit has has build a powerful portfolio of patents, trade secrets, and more than 650 life sciences products. The company was featured on the television series NOVA in 2001, received successive appointments to the Inc. 500 list in 2002 and 2003, and has received numerous local awards including the Rising Star award from the City of Sunnyvale and the Silicon Valley 50 award in 2003. The company changed its name to Arrayit Corporation and began trading on the OTC Bulletin Board in 2009 as ticker symbol ARYC. The company's products and services are used in the life sciences, pharmaceutical, and diagnostics markets, which are estimated at $690 billion in annual revenue.
No share increase per CEO (I.E. NO DILUTION)
Standard Registrar and Transfer Company, Inc.
440 East 400 South, Suite 200
Salt Lake City, UT 84111
Phone: 801-571-8844 or 801-596-2150
Estimated earnings of $8 million last year and it is also located in the heart of Silicon Valley near Apple, Yahoo, AMD, Juniper, MBZ, LinkedIn, Facebook and many, many other leaders of the tech industry.
2 contracts signed last year for a total of approximately $51 million over the next 3 years ......
No other OTC company has the potential of ARYC
Arrayit's new corporate headquarters, features 15,000 square feet of modern industrial space including 45 parking spaces, offices, conference rooms, demonstration laboratories, class 100 cleanrooms, and manufacturing and shipping facilities
Arrayit Headquarters Drive By(Click to view)
Arrayit Store sales exceed $55,000,000 all time on 230,706 products and services sold since on-line inception
ARYC also owns 40 million shares of AVDX(Click to visit Advant Diagnostics)
Enabling physicians to make personalized treatment recommendations for cancer patients
Avant Diagnostics, Inc. (formerly known as Theranostics Health, Inc.) is a medical diagnostic technology company focused on commercializing innovative biomarker technologies that have the potential to dramatically improve treatment outcomes in the areas of oncology and neurology. The Company's lead technology, called Theralink(r), was developed to empower cancer treating physicians with actionable information make time sensitive treatment decisions for their patients. Theralink was designed to inform physicans which treatments are likely to be effective for their patients at any given moment in time, and also identify which treamtents are unlikely to be effective. This information has the potential to improve treatment efficacy and reduce side effects by foregoing ineffective therapy.
Cancer tumor biomarker profiling: Driving innovation in personalized medicine
At Avant Diagnostics, our approach is based on more than 10 years of research and development that informs our philosophy the genetic information alone is insufficient to make patient specific treatment recommendations. Our phospho-proteomic approach, which focuses on measuring the quantity and intensity of drug target activation in the tumor tissue following standard biopsy procedures, exploits our understanding of drug-receptor interaction that is the driver of treatment response . Our advanced technology is being developed to reduce the prescription of ineffective, toxic treatments and guide physicians towards therapies that are most likely to lead to positive responses to treatment. Our large panel of markers targeted at already-approved FDA drugs, as well as certain investigational therapies, makes Theralink an invaluable tool for oncologists.
Market opportunity: Cancer biomarkers market expected to reach $33B by 2025
According to Grand View Research, the market for cancer biomarkers is expected to grow from $10.3B in 2016 to $33.7B by 2025, representing a compound annual growth rate (CAGR) of 14.6%. The market is currently comprised primarily of genetic biomarkers that have good predictive value on a population basis, but limited value on an individual patient basis. Proteomic markers represent a growing segment of the cancer biomarker market, and offer the promise to improve individual patient outcomes based upon the individual patient's tumor proteomic profile.
Within the proteomic cancer biomarker category, phosphoprotein analysis represents a uniquely positioned asset class that can more robustly predict treatment outcomes based upon the molecular mechanisms driving tumor growth and treatment resistance. As such, the Company believes it has the potential to be the market leader in this phospho-proteomic subcategory.
OvaDx® Ovarian Cancer Diagnostic Test
Arrayit Diagnostics, Inc. provides the market's first large panel biomarker screening test for ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA approval, Arrayit Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1®, and transvaginal ultrasound.